Glenmark pharmaceuticals launched Lobeglitazone medicine in India for the treatment of type-2 diabetes in adults. The drug aims to improve insulin resistance in diabetics. To tackle the problem of insulin resistance in type-2 diabetics, Glenmark launched Lobeglitazone in India for the first time. The medicine helps in making body cells more receptive to insulin.
The anti‐diabetic medication will be marketed under the brand name LOBG and will be sold for ₹10 per tablet. Glenmark’s Lobeglitazone will provide not only improve glycemic(sugar) levels in uncontrolled diabetics, but it will also create a new pathway to treat insulin resistance in India.